2025-02-12T12:16:03-06:00 2024-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2023-07-01 135644916 THE LEUKEMIA & LYMPHOMA SOCIETYINC LEUK 9149495213 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 GORDON MILLER JR EVP CHIEF FINANCIAL OFFICER 9149495213 2025-02-12 1 0 DEVIN L DUNCAN P01249521 2127589700 2023 2025-03-06 01:10:19Z X E ANDERS KOLB MD 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 569282300 0 X WWW.LLS.ORG X 1949 NY CURE LEUKEMIA,LYMPHOMA,HODGKIN'S DISEASE, MYELOMA; IMPROVE QUALITY OF LIFE OF PATIENTS AND FAMILIES. 20 20 1228 3000000 0 0 357670634 338611733 9531279 14932514 15134480 16623882 -3997903 -1926070 378338490 368242059 147771106 119474064 0 0 119899883 137851341 4917672 4745743 44198758 113484307 109721024 386072968 371792172 -7734478 -3550113 643891871 602010519 271338303 211058338 372553568 390952181 X OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. 0 0 133673729 64361276 14932514 A) RESEARCH PROGRAMS:AT LLS, WE ARE PUSHING BOUNDARIES TOWARD POWERFUL NEW THERAPIES. WE PROPEL GROUNDBREAKING CANCER TREATMENTS THROUGH ALL PHASES OF THE DRUG APPROVAL PROCESS AND ARE PROUD THAT OUR SUPPORT HAS BEEN KEY TO ADVANCING 75% OF THE ALMOST 70 BLOOD CANCER TREATMENT APPROVALS OVER THE LAST FIVE YEARS.AS WE CONTINUED TO SUPPORT THE SEARCH FOR LIFESAVING AND LESS TOXIC TREATMENTS IN 2024, WE INVESTED IN EXCITING RESEARCH FRONTIERS, INCLUDING PRECISION MEDICINE, IMMUNOTHERAPY, AND LINKS BETWEEN MUTATIONS AND BLOOD CANCER-ADVANCEMENTS THAT ARE CHANGING THE PARADIGM OF CANCER TREATMENT. IN THE PROCESS, WE PROPELLED SEVERAL NOVEL SCIENCE INITIATIVES TO NEW HEIGHTS-MANY OF WHICH HARDLY SEEMED POSSIBLE JUST A SHORT TIME AGO. WITH ADVISORY INPUT FROM RECOGNIZED BIOMEDICAL RESEARCH EXPERTS, LLS FUNDS EXEMPLARY PROJECTS ACROSS THE ENTIRE RESEARCH CONTINUUM RELEVANT TO IMPROVE OUTCOMES FOR BLOOD CANCER PATIENTS, FROM BASIC LABORATORY SCIENCE THROUGH CLINICAL TRIALS. AND FROM INVESTIGATOR-INITIATED RESEARCH TO PRIVATE-SECTOR DRUG DEVELOPMENT ALLIANCES. LLS IS DELIBERATE AND PURPOSEFUL IN FINDING AND SUPPORTING RESEARCH THAT IS MOST LIKELY TO HELP PATIENTS AS SOON AS POSSIBLE. IN ADDITION, WHILE LLS DEDICATES SUBSTANTIAL FUNDING TO ADVANCING NOVEL TREATMENTS FOR BLOOD CANCER, WE ALSO RECOGNIZE THAT IT IS EQUALLY IMPORTANT THAT WE COMMIT TO ENSURING THAT PATIENTS CAN ACCESS THESE ESSENTIAL THERAPIES. TO THIS END, LLS ALSO SUPPORTS HEALTH SERVICES RESEARCH WORKING TO IDENTIFY BARRIERS THAT PREVENT CERTAIN PATIENTS FROM BEING ABLE TO ACCESS THE TREATMENT AND CARE THAT THEY NEED AND FINDING ACTIONABLE SOLUTIONS THAT LLS CAN IMPLEMENT TO OVERCOME THESE BARRIERS AND ADVANCE ITS MISSION. TO DATE, LLS HAS INVESTED OVER $1.8 BILLION IN RESEARCH AIMED AT HELPING ALL BLOOD CANCER PATIENTS LIVE BETTER, LONGER LIVES. OUR SUSTAINED RESEARCH INVESTMENT OVER MULTIPLE DECADES HAS PAID OFF HANDSOMELY. THIS IS BEST DEMONSTRATED BY OUR SEMINAL INVESTMENT IN CHIMERIC ANTIGEN RECEPTOR T CELL (CAR T) THERAPY STARTING IN 1990 THAT, SINCE 2017, HAS TRANSLATED INTO 12 FDA-APPROVED CAR T THERAPIES FOR ACUTE B-CELL LEUKEMIA, NON-HODGKIN LYMPHOMA, AND MULTIPLE MYELOMA. CAR T THERAPY HAS IN SOME CASES PRODUCED CURES IN PATIENTS WHO HAVE FAILED ALL OTHER THERAPEUTIC OPTIONS.IN FISCAL YEAR 2024, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 9 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY $65.71 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS.IMPACT RESEARCH GRANTSTO ADDRESS UNEQUAL REPRESENTATION OF UNDERSERVED POPULATIONS IN CLINICAL TRIALS, IN 2021 WE ACTIVATED IMPACT (INFLUENTIAL MEDICINE PROVIDING ACCESS TO CLINICAL TRIALS) RESEARCH GRANTS. AN INITIAL FIVE-YEAR INVESTMENT OF $3.75 MILLION WAS ALLOCATED TO MAYO CLINIC, VANDERBILT UNIVERSITY MEDICAL CENTER, AND WEILL CORNELL MEDICINE IN NEW YORK CITY. WE NOW HAVE SIX IMPACT RESEARCH GRANTS IN PLACE SINCE OCTOBER 2022. THE IMPACT GRANTS WILL HELP THESE MAJOR CANCER CENTERS EXPAND CLINICAL TRIAL ACCESS TO LOCAL COMMUNITY-BASED HOSPITALS AND CLINICS WITH SUBSTANTIAL UNDERSERVED POPULATIONS. THE GOAL IS TO INCREASE TRIAL ENROLLMENT AMONG TRADITIONALLY UNDERSERVED POPULATIONS, INCLUDING RACIAL AND ETHNIC MINORITIES, RURAL RESIDENTS, AND INDIVIDUALS WITH LOW INCOME, THEREBY EXPANDING ACCESS TO STATE-OF-THE-ART THERAPIES TO A BROADER SWATH OF NEWLY DIAGNOSED BLOOD CANCER PATIENTS.EQUITY IN ACCESS RESEARCH PROGRAM IN 2022, LLS LAUNCHED THE EQUITY IN ACCESS RESEARCH PROGRAM, WHICH AIMS TO FUND RESEARCH THAT WILL GENERATE ACTIONABLE EVIDENCE TO ASSIST LLS IN ADVOCATING FOR CHANGES IN HEALTHCARE POLICY, DEVELOPING PATIENT-FACING PROGRAMS, AND FOSTERING PRACTICE CHANGE TO PROVIDE ALL PATIENTS WITH A FAIR AND JUST OPPORTUNITY TO SURVIVE WITH THE OPTIMAL QUALITY OF LIFE. SINCE INCEPTION OF THIS PROGRAM, LLS HAS AWARDED MORE THAN $5 MILLION TO PROJECTS ADDRESSING CRITICAL ISSUES SUCH AS THE COST OF ORAL ANTICANCER MEDICATIONS, ACCESS TO HEALTH INSURANCE, ACCESS TO SPECIALIZED CANCER CARE AMONG ADOLESCENTS AND YOUNG ADULTS, AND RACIAL DISPARITIES IN ACCESS TO HIGH-QUALITY END-OF-LIFE CARE. LLS RECOGNIZES THE CRITICAL NEED FOR EVIDENCE ON INTERVENTIONS TO INCREASE CANCER CLINICAL TRIAL PARTICIPATION, PARTICULARLY AMONG UNDERREPRESENTED GROUPS (I.E., ETHNIC AND RACIAL MINORITIZED GROUPS, INDIVIDUALS WITH LOW INCOME, OLDER ADULTS, AND PEOPLE WHO LIVE IN RURAL AREAS), AND WILL PRIORITIZE THIS RESEARCH THROUGH THE EQUITY IN ACCESS RESEARCH PROGRAM TO INCREASE ACCESS TO CLINICAL TRIALS, WHICH ARE CONSIDERED HIGH-QUALITY CANCER CARE. THERAPY ACCELERATION PROGRAM (TAP)TAP IS LLS' MISSION-DRIVEN, STRATEGIC VENTURE PHILANTHROPY INITIATIVE THAT SEEKS TO ACCELERATE THE DEVELOPMENT OF INNOVATIVE BLOOD CANCER THERAPEUTICS AND CHANGE THE STANDARD OF CARE. TAP COLLABORATES WITH BIOTECH COMPANIES TO SUPPORT THE DEVELOPMENT OF NOVEL PLATFORMS, FIRST-IN-CLASS ASSETS ADDRESSING UNMET MEDICAL NEEDS, EMERGING PATIENT POPULATIONS AND EVEN RARE BLOOD CANCERS.ESTABLISHED IN 2007, TAP HAS INVESTED MORE THAN $110 MILLION IN OVER 50 BIOTECH COMPANY PROJECTS. SINCE 2017, FIVE TAP-SUPPORTED THERAPIES HAVE BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) OR INCLUDED IN THE NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN) GUIDELINES. CURRENTLY, THERE ARE OVER 30 ACTIVE CLINICAL STUDIES WITH TAP-SUPPORTED THERAPIES, INCLUDING SEVERAL REGISTRATION-ENABLING CLINICAL STUDIES IN BLOOD CANCER THAT COULD LEAD TO MORE FDA APPROVALS.BETWEEN JULY 2023 AND JUNE 2024 (FY24), TAP MADE INVESTMENTS IN FIVE BIOTECH COMPANIES THAT INCLUDED TWO EXISTING BIOTECH PARTNERS AND THREE BRAND NEW UP-AND-COMING BIOTECH COMPANIES, TO HELP THEM NAVIGATE THE DRUG DEVELOPMENT LANDSCAPE AND TO SUPPORT CLINICAL TRIALS FOR BLOOD CANCER PATIENTS. SEVERAL OF THESE COMPANIES ARE BASED IN EUROPE AND NOW, WITH HELP FROM TAP, THESE COMPANIES ARE RUNNING CLINICAL TRIALS IN THE US.NATIONAL PATIENT REGISTRY COVID INFORMATIONTHE ONGOING COVID-19 PANDEMIC ENGENDERED A HOST OF FEARS AND QUESTIONS FOR THE BLOOD CANCER COMMUNITY. WHEN PATIENT CONCERNS AROSE ABOUT WHETHER THE NEW VACCINES WOULD PROTECT THEM, LLS STEPPED IN TO FIND ANSWERS. IN FEBRUARY 2021, LLS ACTIVATED THE LLS NATIONAL PATIENT REGISTRY, A PROJECT SUPPORTED BY ETHEL AND BERNARD GARIL IN MEMORY OF THEIR SON, MICHAEL, WHO SUCCUMBED TO ACUTE LYMPHOBLASTIC LEUKEMIA. MORE THAN 9,000 BLOOD CANCER PATIENTS ANSWERED THE CALL TO JOIN THE REGISTRY AS "CITIZEN SCIENTISTS." THIS ALLOWED US TO GENERATE THE LARGEST DATA SET REPORTED TO DATE ON VACCINE SAFETY AND EFFICACY (INCLUDING BOOSTERS) ACROSS ALL MAJOR BLOOD CANCER AND TREATMENT TYPES. THIS INFORMATION HAS HELPED PATIENTS, HEALTHCARE PROVIDERS, AND PUBLIC HEALTH OFFICIALS MAKE MORE INFORMED CHOICES ABOUT COVID-19 PREVENTION.CLINICAL TRIALSBEAT AML MASTER TRIALBEGINNING NOVEMBER 2016, LLS LAUNCHED THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. FROM INCEPTION THROUGH JUNE 2024, 491 PATIENTS PARTICIPATED IN CLINICAL TRIALS UNDER THE BEAT AML MASTER TRIAL.IN 2022, LLS LAUNCHED LLS' PEDIATRIC ACUTE LEUKEMIA (PEDAL) MASTER CLINICAL TRIAL. THIS UNPRECEDENTED INTERNATIONAL COLLOBORATION BETWEEN LLS, THE NATIONAL CANCER INSTITUTE (NCI), THE CHILDREN'S ONCOLOGY GROUP (OCG) AND OTHER PARTNERS BREAKS NEW GROUND, BRINGING PRECISION MEDICINE TO THE TREATMENT OF PEDIATRIC RELAPSED ACUTE LEUKEMIA. RATHER THAN A "ONE SIZE FITS ALL" APPROACH, PEDAL USES GENOMICS AND OTHER BIOMARKERS TO CUSTOMIZE TREATMENT, ALLOWING INNOVATIVE THERAPIES TO BE MATCHED TO PATIENTS BASED ON THEIR UNIQUE TUMOR BIOLOGY. A WIDE RANGE OF TRIAL SCREENIN LOCATIONS - SPANNING EUROPE, AUSTRALIA, NEW ZEALAND, CANADA, AND OVER 200 US SITES - ENSURES WIDESPREAD PARTICIPATION. 104363302 55112788 B) PATIENT & COMMUNITY SERVICES:AN ESTIMATED 1.7 MILLION PEOPLE ACROSS THE UNITED STATES (US) ARE CURRENTLY LIVING WITH OR ARE IN REMISSION FROM LEUKEMIA, LYMPHOMA AND MYELOMA. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) OFFERS AN ARRAY OF FREE, COMPREHENSIVE RESOURCES TO BLOOD CANCER PATIENTS, CAREGIVERS, FAMILIES AND FRIENDS OF PATIENTS, ADVOCATES, HEALTHCARE PROFESSIONALS AND THE PUBLIC. LLS IS COMMITTED TO PROVIDING THE MOST ACCURATE AND UP-TO-DATE BLOOD CANCER INFORMATION. PROFESSIONAL VOLUNTEER CLINICAL ADVISORS WORK WITH LLS STAFF TO REVIEW ALL OF THE INFORMATION LLS PROVIDES THROUGH HEALTHCARE PROFESSIONAL AND PATIENT EDUCATION PROGRAMS, PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE-TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS.FINANCIAL ASSISTANCEOUR FINANCIAL ASSISTANCE PROGRAMS AIM TO LESSEN THE ECONOMIC TOLL ON PATIENTS AND FAMILIES TO HELP PATIENTS AFFORD LIFE-SAVING TREATMENTS. TO COUNTER CONTINUALLY RISING DRUG PRICES AND ALLEVIATE THE BURDENS FELT BY PATIENTS COPING WITH BLOOD CANCER, LLS PROVIDED 70,982 GRANTS TOTALING OVER $173M IN ASSISTANCE AWARDED. THE LION'S SHARE-OVER $158 MILLION- AWARDED TO SUPPORTED PATIENTS' INSURANCE PREMIUMS AND TREATMENT-RELATED CO-PAY AND CO-INSURANCE OUT OF POCKET COSTS THROUGH OUR CO-PAY ASSISTANCE PROGRAM.IN KEEPING WITH OUR COMMITMENT TO DIVERSITY, EQUITY, AND INCLUSION, LLS RECOGNIZES THAT NEED EXISTS THROUGHOUT ALL GEOGRAPHIC REGIONS AND WITHIN ALL PATIENT POPULATIONS, INCLUDING THOSE TRADITIONALLY UNDERREPRESENTED. CO-PAY ASSISTANCE PROGRAMTHE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2024, LLS AWARDED 29,605 GRANTS THROUGH ITS CO-PAY ASSISTANCE PROGRAM.SUSAN LANG PRE CAR T-CELL THERAPY TRAVEL ASSISTANCE PROGRAMLLS AWARDED 425 GRANTS EACH IN THE AMOUNT OF $2,500 FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS FOR PATIENTS WHO ARE BEING EVALUATED TO RECEIVE CAR T-CELL THERAPY AS EITHER STANDARD TREATMENT OR A CLINICAL TRIAL.SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAMLLS AWARDED 2,079 GRANTS EACH IN THE AMOUNT OF $500 FOR TREATMENT-RELATED TRANSPORTATION AND LODGING COSTS.URGENT NEED PROGRAMIN PARTNERSHIP WITH MOPPIE'S LOVE AND CHARLIE'S FUND, LLS AWARDED 15,838 GRANTS EACH IN THE AMOUNT OF $500 FOR NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD.LOCAL FINANCIAL ASSISTANCE PROGRAM LLS AWARDED 4,339 GRANTS EACH IN THE AMOUNT OF $500 TO COVER NON-MEDICAL LIVING EXPENSES-INCLUDING RENT, UTILITIES, AND FOOD, ETC. PATIENT AID PROGRAM LLS AWARDED ONE-TIME STIPENDS OF $100 TO OVER 18,696 PATIENTS TO HELP OFFSET NON-MEDICAL EXPENSES. SCHOLARSHIP FOR BLOOD CANCER SURVIVORSIN 2024, THE LLS SCHOLARSHIP FOR BLOOD CANCER SURVIVORS AWARDED 236 SCHOLARSHIPS EACH UP TO $7,500 IN TUITION SUPPORT FOR VIRTUAL OR IN-PERSON VOCATIONAL, TWO-YEAR, ORFOUR-YEAR UNDERGRADUATE EDUCATION. 23265032 C) PUBLIC HEALTH EDUCATION:LLS BELIEVES KNOWLEDGE IS POWER. AS ALWAYS, LLS HAS OFFERED THEIR INFORMATIONAL PROGRAMS IN VIRTUAL FORMATS, CONTINUING TO PROVIDE VITALLY NEEDED EDUCATION AND EMOTIONAL SUPPORT FOR THOSE IMPACTED BY BLOOD CANCER. ONE-ON-ONE EDUCATION AND SUPPORTTRAINED ONCOLOGY INFORMATION SPECIALISTS IN OUR INFORMATION RESOURCE CENTER (IRC) PROVIDE PATIENTS AND CAREGIVERS WITH COMPASSIONATE, COMPREHENSIVE, AND TAILORED DISEASE AND TREATMENT INFORMATION, INCLUDING REFERRALS AND LINKS TO APPROPRIATE EDUCATIONAL RESOURCES AND LITERATURE; PSYCHOSOCIAL SUPPORT INFORMATION FOR ANY POINT IN THEIR TREATMENT JOURNEY; REFERRALS TO RELEVANT LOCAL, STATE AND/OR NATIONAL RESOURCES FOR ASSISTANCE; COVID-19 RELATED INFORMATION AND GUIDANCE; AND FINANCIAL RESOURCE INFORMATION TO COVER COSTS OF TREATMENT, TRAVEL, URGENT NEEDS AND MORE. OVER 25,000 INTERACTIONS BETWEEN THE IRC AND PATIENTS AND CAREGIVERS TOOK PLACE LAST YEAR.FACILITATING CLINICAL TRIAL ACCESSTHE LLS CLINICAL TRIAL SUPPORT CENTER (CTSC) GREW THROUGHOUT THE YEAR AS WE INCREASED OUR BI-LINGUAL AND PEDIATRIC EXPERTISE AMONG THE CTSC NURSE NAVIGATORS, AND CONTINUED TO EXPAND THE POSSIBILITY OF POSITIVE OUTCOMES FOR PATIENTS BY MATCHING THEM TO SUITABLE CLINICAL TRIALS. OUR NURSE NAVIGATORS ASSISTED 1077 PATIENTS. TWENTY PERCENT OF THESE PATIENTS ENTERED A TRIAL.OUTREACH TO UNDERSERVED GROUPSWE AUGMENTED EFFORTS TO EXPAND ACCESS TO LLS SERVICES AND RESOURCES BY BOLSTERING RELATIONS WITH COMMUNITY GROUPS AND LEADERS, NOTABLY IN THE BLACK AND LATINO COMMUNITIES, AND INCREASED OUR NUMBER OF BILINGUAL STAFF AND VOLUNTEERS. WE ALSO INCREASED ACCESSIBILITY OF OUR EDUCATION PROGRAMS TO RURAL PATIENTS AND FAMILIES VIA OUR VIRTUAL OFFERINGS. MOREOVER, WE EXPANDED PARTNERSHIPS WITH ADDITIONAL AFFINITY GROUPS INCLUDING: THE NATIONAL HISPANIC NURSES ASSOCIATION, NATIONAL ASSOCIATION OF COMMUNITY HEALTH WORKERS, THE LATINO CANCER INSTITUTE, NATIONAL BLACK NURSES ASSOCIATION, ALPHA PHI ALPHA.THE LLS MYELOMA LINK PROGRAM, LAUNCHED IN 2017, CONTINUED TO GAIN TRACTION. WE IMPROVED UNDERSTANDING OF TREATMENT OPTIONS BY PROVIDING IMPORTANT INFORMATION TO AFRICAN AMERICANS, WHO ARE TWICE AS LIKELY TO BE DIAGNOSED WITH MULTIPLE MYELOMA AS CAUCASIAN AMERICANS. IN 2024, LLS REACHED ALMOST 25,000 PEOPLE THROUGH MYELOMA LINK EDUCATION AND OUTREACH ACTIVITIES IN 15 CITIES ACROSS THE U.S.IN 2024, THE LLS LATINO OUTREACH PILOT REACHED APPROXIMATELY 100,000 SPANISH-SPEAKING COMMUNITY MEMBERS THROUGH COMMUNITY PROGRAMS ACROSS 5 MAJOR HISPANIC MARKETS (INCLUDING PR) AND OUR PARTNERSHIP WITH ENTRAVISION AND PRIME TIME INTERVIEWS WITH BOTH UNIVISION AND TELEMUNDO. EDUCATION AND PATIENT CONNECTIONSOUR VIRTUAL EDUCATION PROGRAMS PROVIDED BOTH PATIENTS AND FAMILIES, AS WELL AS HEALTH CARE PROFESSIONALS, ACCESS TO CONTENT INCLUDING BLOOD CANCER CONFERENCES, LOCAL EDUCATION PROGRAMS, NATIONAL WEBINARS, VIDEOS, LECTURES, AND PODCASTS.LLS'S HIGHLY VIEWED WEBSITE CONTINUES TO PROVIDE THE MOST UP TO DATE BLOOD CANCER INFORMATION INCLUDING ACCESS TO BLOGS, BOOKLETS, WORKBOOKS, FACT SHEETS AND MORE. IN ADDITION, 1,638 CANCER PATIENTS WERE PROVIDED WITH PERSONALIZED NUTRITION CONSULTATIONS BY LLS'S REGISTERED DIETITIANS. OUR PATIENT & COMMUNITY OUTREACH TEAM CONTINUED TO BRING PATIENTS TOGETHER VIA ONLINE LOCAL SUPPORT GROUPS AND CHATS. THE PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM MATCHED 2,200 PATIENTS WITH TRAINED VOLUNTEERS FACING THE SAME DISEASE.IN ADDITION, MEMBERSHIP IN LLS COMMUNITY-OUR ONLINE SOCIAL NETWORK- WAS 22,796, AN INCREASE OF 9% OVER FISCAL YEAR 2023. 16017073 D) PROFESSIONAL EDUCATION:LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL DEPARTMENT OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE.IN FY 2024:-LLS PROVIDED 17 CME/CE-GRANTING LIVE EDUCATIONAL PROGRAMS, WITH 2,533 HEALTHCARE PROFESSIONALS IN ATTENDANCE. IN ADDITION 36 VIRTUAL LECTURES WERE PRESENTED WITH ALMOST 65,000 PARTICIPANTS.- OVER 22,000 PATIENTS AND PROFESSIONALS PARTICIPATED IN LIVE EDUCATION PROGRAMS DELIVERED VIRTUALLY AS WELL AS DELIVERED IN PERSON, LOCALLY AND REGIONALLY.-THERE WERE OVER 214,000 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS, VIRTUAL LECTURES AND VIDEOS AND NEARLY 90,000 PODCAST DOWNLOADS. OVER 911,000 BOOKLETS AND FACT SHEETS WERE EITHER DOWNLOADED OR ORDERED IN HARD COPY. 16017073 277319136 1 1 0 1 0 0 0 1 1 1 1 0 0 0 1 1 0 1 0 1 1 1 0 1 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 368 0 1 1228 1 0 1 CA 0 0 0 1 1 0 0 0 0 1 0 X 20 20 0 0 1 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 0 AK AL AR AZ CA CO CT DE DC FL GA HI ID IL IN KS KY LA MA MD ME MI MN MO MS NH NJ NM NE NY OH OK OR PA PR RI SC TN UT VA WA WI WV X X GORDON MILLER JR 9148218935 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 JEFF SACHS CHAIR 4.00 0.00 X X 0 0 0 KATHLEEN MERIWETHER VICE CHAIR 4.00 0.00 X X 0 0 0 FREDA WANG SECRETARY/TREASURER 4.00 0.00 X X 0 0 0 JANICE GABRILOVE MD AT LARGE 4.00 0.00 X X 0 0 0 LEROY BALL BOD MEMBER 4.00 0.00 X 0 0 0 RICHARD BAGGER BOD MEMBER 4.00 0.00 X 0 0 0 MARK BAEEENECHEA BOD MEMBER 4.00 0.00 X 0 0 0 RENZO CANETTA MD BOD MEMBER 4.00 0.00 X 0 0 0 CASEY CUNNINGHAM MD BOD MEMBER 4.00 0.00 X 0 0 0 HELEN HESLOP BOD MEMBER 4.00 0.00 X 0 0 0 ARI MELNICK BOD MEMBER 4.00 0.00 X 0 0 0 RUBEN MESA BOD MEMBER 4.00 0.00 X 0 0 0 LYNNE O'BRIEN BOD MEMBER 4.00 0.00 X 0 0 0 MARLA PERSKY BOD MEMBER 4.00 0.00 X 0 0 0 JIM REDDOCH BOD MEMBER 4.00 0.00 X 0 0 0 RICHARD RENDINA BOD MEMBER 4.00 0.00 X 0 0 0 ROBERT ROSEN BOD MEMBER 4.00 0.00 X 0 0 0 BART SICHEL BOD MEMBER 4.00 0.00 X 0 0 0 ALESSANDRA TOCCO BOD MEMBER 4.00 0.00 X 0 0 0 YVETTE TREMONTI BOD MEMBER 4.00 0.00 X 0 0 0 E ANDERS KOLB - START 512023 PRESIDENT & CEO 40.00 0.00 X 471613 0 8226 GWEN NICHOLS EVP, CHIEF MEDICAL OFC 40.00 0.00 X 526284 0 50687 TROY DUNMIRE EVP, CHIEF OPERATING OFC 40.00 0.00 X 510557 0 49364 DALE NISSENBAUM EVP, GENERAL COUNSEL 40.00 0.00 X 497291 0 30459 GORDON MILLER JR EVP, CHIEF FINANCIAL OFC 40.00 0.00 X 453172 0 58818 COKER POWELL SVP, CHIEF DEVELOPMENT OFC 40.00 0.00 X 388870 0 31076 VANESSA WHITE SVP, CHIEF ADVANCEMENT OFC 40.00 0.00 X 380333 0 35565 SUSAN BROWN SVP, CHIEF DEI OFC 40.00 0.00 X 382991 0 47279 LEE GREENBERGER SVP, CHIEF SCIENTIFIC OFC 40.00 0.00 X 377058 0 45160 FLORENCE GODFREY SVP, CHIEF EXPERIENCE OFC 40.00 0.00 X 341009 0 44689 LOUIS JDEGENNARO-END 63023 PRESIDENT & CEO - FORMER 40.00 0.00 X 1358093 0 25701 5687271 0 427024 193 1 1 0 ICON PLC - PHARMACEUTICAL RESEARCH ASSOC 4130 PARKLAKE AVENUE SUITE 400 RALEIGH NC 27612 CLINICAL TRIAL 10155555 PATIENT ADVOCATE FOUNDATION 421 BUTLER FARM RD HAMPTON VA 23666 PAT ASSIST PROC 7679383 SALESFORCE 140 E 45TH ST NEW YORK NY 10017 SOFTWARE 3860428 RESOURCE ONE COMMUNICATIONS 2900 EAST APACHE STREET TULSA OK 74110 DIRECT MARKETING 3105900 META PLATFORMS 1 HACKER WAY MENLO PARK CA 94025 ADVERTISING 3037751 368 462018 134689222 203460493 3270884 338611733 SERVICE REVENUE 810000 14932514 14932514 14932514 14243283 14243283 3795808 3795808 180888282 178507683 2380599 2380599 2380599 16810680 134689222 22532558 -5721878 -5721878 368242059 14932514 0 14697812 X 52558533 52558533 55112788 55112788 11802743 11802743 2070059 878840 856433 334786 107937447 66562775 22886622 18488050 3595798 2191206 813097 591495 16388463 10012920 3667835 2707708 7859574 4789465 1777240 1292869 2731853 1639112 737600 355141 409995 409995 4125292 4125292 4745743 4745743 236608 180162 28363 28083 21893141 14796303 3927127 3169711 8557338 5515795 818627 2222916 14860478 9195933 1336863 4327682 13204094 995589 9808001 2400504 3897493 2625114 625947 646432 10324815 7868519 1296088 1160208 5425197 3371985 1169149 884063 1154429 710625 257105 186699 RESEARCH & DEVELOPMENT 18281905 18281905 MISCELLANEOUS 4618386 4103532 -141814 656668 371792172 277319136 50274278 44198758 X 21290012 13907952 0 7382060 1093408 3858985 87996059 143907675 29923480 45469673 5045849 5836452 31315227 20562994 13251184 10752233 463285795 353960098 20291527 22812891 10015427 11136057 516667 316667 12472475 3959788 643891871 602010519 21647040 36559192 219704797 155633120 15561185 14667950 0 14425281 4198076 271338303 211058338 X 281881454 251301743 90672114 139650438 372553568 390952181 643891871 602010519 X -3550113 21613526 335200 X 0 1 X 1 0 X 427419530 441317494 400540019 357670634 338611733 1965559410 427419530 441317494 400540019 357670634 338611733 1965559410 553410745 1412148665 29082073 16877123 18087763 13066416 18039091 95152466 2060711876 68499130 0.68530 0.68950 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 1 1087778 0 1 1029920 0 1 763999 1 580545 1 663050 4125292 0 PART II-B, LINE 1: LLS PARTICIPATES IN A NUMBER OF COALITIONS AND MEMBER ORGANIZATIONS, INCLUDING ALLIANCE FOR A STRONGER FDA, ALLIANCE FOR CHILDHOOD CANCER, ALLIANCE FOR FAIR HEALTHCARE PRICING, CANCER LEADERSHIP COUNCIL, DEFENSE HEALTH RESEARCH CONSORTIUM, MAPRX COALITION, NCSL FOUNDATION FOR STATE LEGISLATURES, ONE VOICE AGAINST CANCER, PARTNERSHIP TO PROTECT COVERAGE, PATIENT QUALITY OF LIFE COALITION, PUBLIC AFFAIRS COUNCIL, AND STATE ACCESS TO INNOVATIVE MEDICINES COALITION. EMPLOYEES IN THE LLS OFFICE OF PUBLIC POLICY WORK TO ADVANCE THE ORGANIZATION'S PUBLIC POLICY PRIORITIES, DOING SO WITH SUPPORT FROM LOBBYING FIRMS AND ADVISERS RETAINED BY LLS AND IN PARTNERSHIP WITH VOLUNTEER ADVOCATES. LLS VOLUNTEER ADVOCATES ENGAGE THEIR LAWMAKERS BY CONDUCTING LETTER-WRITING CAMPAIGNS, SHARING THEIR PERSONAL STORIES, AND CONDUCTING ONE-ON-ONE VISITS IN STATE CAPITOLS AND IN WASHINGTON, D.C. ALL WITH SUPPORT FROM THE LLS OFFICE OF PUBLIC POLICY. 0 1 0 1000000 1000000 1 7730391 80666 787363 308062 13050 8277308 7288293 30000 713739 291598 10043 7730391 7381460 1129903 -913685 295324 14061 7288293 5902791 1650 1726314 236177 13118 7381460 6168319 -8812 246718 9998 5902791 0.60190 0.39810 0 0 1038869 945434 93435 30224812 19566014 10658798 51546 51546 0 10752233 CAPITAL LEASE LIABILITY 4198076 4198076 X 388210511 -2380597 12063656 10522001 20205060 368005451 236608 236608 368242059 394745114 12063656 11125894 23189550 371555564 236608 236608 371792172 PART III, LINE 1A: THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. PART IV, LINE 1B: LLS HELD $1 MILLION IN ESCROW ON BEHALF OF IFLI AS PART OF A PASS-THROUGH GRANT AGREEMENT. PART V, LINE 4: LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. PART X, LINE 2: LLS, LLSRP, AND LLSRF QUALIFY AS CHARITABLE ORGANIZATIONS AS DEFINED BY INTERNAL REVENUE CODE SECTION 501(C)(3) AND, ACCORDINGLY, ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). ADDITIONALLY, SINCE THESE ORGANIZATIONS ARE PUBLICLY SUPPORTED, CONTRIBUTIONS QUALIFY FOR THE MAXIMUM CHARITABLE CONTRIBUTION DEDUCTION UNDER THE INTERNAL REVENUE CODE. LLSC IS REGISTERED AS A CHARITABLE ORGANIZATION UNDER THE INCOME TAX ACT (CANADA) AND IS, THEREFORE, NOT SUBJECT TO INCOME TAXES IF CERTAIN DISBURSEMENT REQUIREMENTS ARE MET. LLS AND ITS RELATED ENTITIES RECOGNIZE THE EFFECT OF TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THERE WERE NO ENTITIES THAT RECOGNIZED UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2024 AND JUNE 30, 2023. PART XI, LINE 2D - OTHER ADJUSTMENTS: LLS CANADA REVENUE 10,522,001. PART XII, LINE 2D - OTHER ADJUSTMENTS: LLS CANADA EXPENSE 11,125,894. 1 NORTH AMERICA 1 RESEARCH FUNDING RESEARCH GRANTS 1503560 EUROPE RESEARCH FUNDING RESEARCH GRANTS 7930983 CENTRAL AMERICA & CARIBBEAN INVESTMENTS INVESTMENTS 9358822 EAST ASIA & THE PACIFIC RESEARCH FUNDING RESEARCH GRANTS 2368200 EUROPE INVESTMENTS INVESTMENTS 8036661 1 0 0 0 1 0 29198226 0 29198226 EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 249656 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 249500 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 249975 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 249069 WIRE PAYMENT 0 ACCRUAL EAST ASIA & THE PACIFIC RESEARCH GRANTS 120000 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 125000 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 150000 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 150000 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 78600 WIRE PAYMENT 0 ACCRUAL NORTH AMERICA RESEARCH GRANTS 999960 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 31667 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 750000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 496337 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 125000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 50000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 249977 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 250000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 231171 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 1700000 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 425841 WIRE PAYMENT 0 ACCRUAL EUROPE RESEARCH GRANTS 186861 WIRE PAYMENT 0 ACCRUAL EUROPE THERAPY ACCELERATION 3181189 WIRE PAYMENT 0 FMV 0 29 1 0 1 1 0 0 PART I, LINE 2: FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS. X X X X X X X 1 THOMPSON HABIB & DENISON 80 HAYDEN AVENUE SUITE 300 LEXINGTON MA 02421 DIRECT MAIL 0 0 413042 -413042 RESOURCE ONE 2900 EAST APACHE STREET TULSA OK 74110 DIRECT MAIL 0 0 3105900 -3105900 3518942 -3518942 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY DC PR LAKE TAHOE BIKE RIDE 2840907 2354726 486181 86656 226676 73728 103761 99687 HOUSTON STUDENT VISIONARIES 2803106 2672567 130539 23792 39331 88948 8170 1750 260 145855889 129661929 16193960 2185838 13808655 3386465 1695286 703815 151499902 134689222 16810680 2296286 14074662 3549141 1807217 805252 22532558 -5721878 SCHEDULE G, PART I, LINE 2B, COLUMN (V) LLS USED RESOURCE ONE AND THOMPSON HABIB, & DENISON FOR IT'S NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. 1 COLUMBIA UNIVERSITY MEDICAL CENTER 535 W 116TH ST NEW YORK NY 10027 135598093 501(C)(3) 1200000 0 ACCRUAL RESEARCH GRANT ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10461 472209056 501(C)(3) 1189743 0 ACCRUAL RESEARCH GRANT ATRIUM HEALTH FOUNDATION 7800 PROVIDENCE RD CHARLOTTE NC 28226 566060481 501(C)(3) 124866 0 ACCRUAL RESEARCH GRANT BAYLOR COLLEGE OF MEDICINE PO BOX 301207 DALLAS TX 75303 741613878 501(C)(3) 222716 0 ACCRUAL RESEARCH GRANT BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953432210 501(C)(3) 806250 0 ACCRUAL RESEARCH GRANT BOSTON CHILDREN'S HOSPITAL PO BOX 414413 BOSTON MA 02241 042774441 501(C)(3) 500000 0 ACCRUAL RESEARCH GRANT CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVENUE CINCINATTI OH 45229 310833936 501(C)(3) 840000 0 ACCRUAL RESEARCH GRANT CLEVELAND CLINIC FOUNDATION 9500 EUCLID AVENUE CLEVELAND OH 44195 340714585 501(C)(3) 150000 0 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 4743450 0 ACCRUAL RESEARCH GRANT DREN BIO 384 FOSTER CITY BLVD FOSTER CITY CA 94404 841826535 3200000 0 FMV THERAPY ACCELERATION DUKE UNIVERSITY MEDICAL CENTER PO BOX 602651 CHARLOTTE NC 28260 560532129 501(C)(3) 194977 0 ACCRUAL RESEARCH GRANT EMORY UNIVERSITY PO BOX 935084 ATLANTA GA 31193 582137993 501(C)(3) 1591088 0 ACCRUAL RESEARCH GRANT FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 237156071 501(C)(3) 1438989 0 ACCRUAL RESEARCH GRANT GEORGE WASHINGTON UNIVERSITY 2121 I ST NW WASHINGTON DC 20052 530196584 501(C)(3) 250000 0 ACCRUAL RESEARCH GRANT H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE PO BOX 742801 ATLANTA GA 30374 593238634 501(C)(3) 2062118 0 ACCRUAL RESEARCH GRANT HOUSTON METHODIST RESEARCH INSTITUTE 6670 BERTNER AVENUE HOUSTON TX 77030 870721923 501(C)(3) 500000 0 ACCRUAL RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 577750 0 ACCRUAL RESEARCH GRANT IMMUNITAS THERAPEUTICS INC 21 HICKORY DR WALTHAM MA 02451 842813217 95605 0 ACCRUAL RESEARCH GRANT INDIANA UNIVERSITY 2101 E COLISEUM BLVD FORT WAYNE IN 46805 356001673 501(C)(3) 546000 0 ACCRUAL RESEARCH GRANT INTERNATIONAL WALDENSTROM'S MACROGLOBULINEMIA FOUNDATION 6144 CLARK CENTER AVE SARASOTA FL 34238 541784426 501(C)(3) 50000 0 ACCRUAL RESEARCH GRANT JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 575 LEXINGTON AVE NEW YORK NY 10022 131623978 501(C)(3) 2365000 0 ACCRUAL RESEARCH GRANT MAINE MEDICAL CENTER 22 BRAMHALL STREET PORTLAND ME 04102 010238552 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 02241 041564655 501(C)(3) 1000000 0 ACCRUAL RESEARCH GRANT MAYO CLINIC ROCHESTER PO BOX 860334 MINNEAPOLIS MN 55486 416011702 501(C)(3) 275000 0 ACCRUAL RESEARCH GRANT MPN RESEARCH PO BOX 10743 CHICAGP IL 60610 364330967 501(C)(3) 50000 0 FMV THERAPY ACCELERATION MYELOPROLIFERATIVE NEOPLASMS RESEARCH FOUNDATION PO BOX 2690 CAROL STREAM IL 60601 364330967 501(C)(3) 100000 0 ACCRUAL RESEARCH GRANT NORTHWESTERN UNIVERSITY 633 CLARK AVE EVANSTON IL 60208 362167817 501(C)(3) 598047 0 ACCRUAL RESEARCH GRANT NYU GROSSMAN SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562308 501(C)(3) 245940 0 ACCRUAL RESEARCH GRANT OREGON HEALTH & SCIENCE UNIVERSITY CANCER INSTITUTE 3181 SW SAM JACKSON PARK ROAD PORTLAND OR 97239 237083114 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT OSU FOUNDATION 1960 KENNY ROAD 4TH FLOOR COLUMBUS OH 43210 316025986 GOVT 546652 0 ACCRUAL RESEARCH GRANT PERELMAN SCHOOL OF MEDICINE AT THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET FRANKLIN BLDG P-221 PHILADELPHIA PA 19104 231352685 501(C)(3) 950000 0 ACCRUAL RESEARCH GRANT PRESIDENT AND FELLOWS OF HARVARD COLLEGE MASSACHUSETTS HALL CAMBRIDGE MA 02138 042103580 501(C)(3) 100000 0 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIGAN PO BOX 223131 PITTSBURGH PA 15251 386006309 501(C)(3) 250000 0 ACCRUAL RESEARCH GRANT RHODE ISLAND HOSPITAL 593 EDDY STREET PROVIDENCE RI 02903 050258954 501(C)(3) 125000 0 ACCRUAL RESEARCH GRANT RUTGERS UNIVERSITY 3 RUTGERS PLAZA NEW BRUNSWICK NJ 08901 226001086 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 911156519 501(C)(3) 31250 0 ACCRUAL RESEARCH GRANT SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH PO BOX 026338 NEW YORK NY 10087 131924236 501(C)(3) 2237344 0 ACCRUAL RESEARCH GRANT ST JUDE CHILDREN'S RESEARCH HOSPITAL PO BOX 1000 DEPT 949 MEMPHIS TN 38148 620646012 501(C)(3) 1326339 0 ACCRUAL RESEARCH GRANT TEXAS A&M UNIVERSITY HEALTH SCIENCE CENTER 8441 RIVERSIDE PKWY BRYAN TX 77807 742907553 GOVT 312500 0 ACCRUAL RESEARCH GRANT THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 450 SERRA MALL STANFORD CA 94305 941156365 501(C)(3) 2452718 0 ACCRUAL RESEARCH GRANT THE BRIGHAM AND WOMENS HOSPITAL INC PO BOX 3149 BOSTON MA 02241 042312909 501(C)(3) 135000 0 ACCRUAL RESEARCH GRANT THE CHILDREN'S HOSPITAL OF PHILADELPHIA PO BOX 8500 PHILADELPHIA PA 19178 231352166 501(C)(3) 315000 0 ACCRUAL RESEARCH GRANT THE JACKSON LABORATORY 600 MAIN STREET BAR HARBOR ME 04609 010211513 501(C)(3) 130000 0 ACCRUAL RESEARCH GRANT THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE 12529 COLLECTIONS CENTER DRIVE CHICAGO IL 60693 520595110 501(C)(3) 250000 0 ACCRUAL RESEARCH GRANT THE MEDICAL COLLEGE OF WISCONSIN INC 8701 W WATERTOWN PLANK RD MILWAUKEE WI 53226 390806261 501(C)(3) 375000 0 ACCRUAL RESEARCH GRANT THE OHIO STATE UNIVERSITY 1960 KENNY ROAD 4TH FLOOR COLUMBUS OH 43210 316025986 501(C)(3) 328124 0 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0009 LA JOLLA CA 92093 956006144 501(C)(3) 690000 0 ACCRUAL RESEARCH GRANT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM ST SAN FRANCISCO CA 94103 946036493 501(C)(3) 875000 0 ACCRUAL RESEARCH GRANT THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER 333 COTTMAN AVENUE PHILADELPHIA PA 19111 232003072 501(C)(3) 599926 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVENUE SOUTH SUITE 1170 AB BIRMINGHAM AL 35294 636005396 GOVT 625000 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF CHICAGO 5841 S MARYLAND AVE MC6092 CHICAGO IL 60637 362177139 501(C)(3) 187000 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS AT AUSTIN 101 E 27TH ST AUSTIN TX 78712 746000203 GOVT 250000 0 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER PO BOX 4266 HOUSTON TX 77210 746001118 GOVT 2453448 0 ACCRUAL RESEARCH GRANT TUFTS MEDICAL CENTER 800 WASHINGTON STREET 453 BOSTON MA 02111 042103634 501(C)(3) 232605 0 ACCRUAL RESEARCH GRANT UNC LINEBERGER COMPREHENSIVE CANCER CENTER 104 AIRPORT DRIVE CHAPEL HILL NC 27599 566001393 501(C)(3) 70000 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES 4301 WEST MARKHAM ST LITTLE ROCK AR 72205 716046242 GOVT 250000 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF COLORADO DENVER ANSCHUTZ MEDICAL CAMPUS PO BOX 6508 AURORA CO 80045 846000555 501(C)(3) 1590000 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF FLORIDA 33 TIGERT HALL GAINESVILLE FL 32611 596002052 501(C)(3) 2210588 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF MIAMI PO BOX 405803 ATLANTA GA 30384 590624458 501(C)(3) 1074768 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF PENNSYLVANIA DEPARTMENT OF MEDICINE 3451 WALNUT STREET FRANKLIN BLDG PHILADELPHIA PA 19104 231352685 501(C)(3) 749214 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF PITTSBURGH 4200 FIFTH AVE PITTSBURGH PA 15260 250965591 501(C)(3) 74475 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF SOUTHERN CALIFORNIA 700 CHILDS WAY LOS ANGELES CA 90089 951642394 501(C)(3) 239560 0 ACCRUAL RESEARCH GRANT UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 22904 237173411 501(C)(3) 999997 0 ACCRUAL RESEARCH GRANT VAN ANDEL RESEARCH INSTITUTE 333 BOSTWICK AVE NE GRAND RAPIDS MI 49503 522000820 501(C)(3) 120000 0 ACCRUAL RESEARCH GRANT VANDERBILT UNIVERSITY MEDICAL CENTER PO BOX 121236 DALLAS TX 75312 620476822 501(C)(3) 371000 0 ACCRUAL RESEARCH GRANT VERSITI BLOOD CENTER OF WISCONSIN 638 N 18TH ST MILWAUKEE WI 53233 390807235 501(C)(3) 37500 0 ACCRUAL RESEARCH GRANT VITTORIA BIOTHERAPEUTICS 3675 MARKET STREET PHILADELPHOA PA 19104 863850050 500000 0 ACCRUAL RESEARCH GRANT WASHINGTON UNIVERSITY IN ST LOUIS 700 ROSEDALE AVENUE ST LOUIS MO 63112 430653611 501(C)(3) 2583235 0 ACCRUAL RESEARCH GRANT YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06520 060646973 501(C)(3) 325000 0 ACCRUAL RESEARCH GRANT 66 3 COPAY ASSISTANCE CLL 9903 25992224 COPAY ASSISTANCE LYMPHOMA 4960 12367827 COPAY ASSISTANCE MDS 1225 0 COPAY ASSISTANCE MYELOMA 7518 0 COPAY ASSISTANCE MANTEL 149 0 COPAY ASSISTANCE WALDENST 415 1697709 COPAY ASSISTANCE ALL 76 379947 COPAY ASSISTANCE AML 5359 10987710 PATIENT TRAVEL ASSISTANCE 3304 1160225 PATIENT AID 55805 13358106 PART I, LINE 2: FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND OF HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTEN TIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. X X X X X 0 0 0 0 0 0 0 1 0 LOUIS JDEGENNARO-END 63023 PRESIDENT & CEO - FORMER 380343 0 970000 0 7750 0 20790 0 4911 0 1383794 0 0 0 GWEN NICHOLS EVP, CHIEF MEDICAL OFC 440830 0 50000 0 35454 0 16500 0 34187 0 576971 0 0 0 TROY DUNMIRE EVP, CHIEF OPERATING OFC 459027 0 50000 0 1530 0 11550 0 37814 0 559921 0 0 0 DALE NISSENBAUM EVP, GENERAL COUNSEL 442974 0 50000 0 4317 0 11550 0 18909 0 527750 0 0 0 GORDON MILLER JR EVP, CHIEF FINANCIAL OFC 401060 0 50000 0 2112 0 16500 0 42318 0 511990 0 0 0 E ANDERS KOLB - START 512023 PRESIDENT & CEO 470244 0 0 0 1369 0 0 0 8226 0 479839 0 0 0 SUSAN BROWN SVP, CHIEF DEI OFC 379359 0 0 0 3632 0 16500 0 30779 0 430270 0 0 0 LEE GREENBERGER SVP, CHIEF SCIENTIFIC OFC 346994 0 20000 0 10064 0 11550 0 33610 0 422218 0 0 0 COKER POWELL SVP, CHIEF DEVELOPMENT OFC 365009 0 0 0 23861 0 11550 0 19526 0 419946 0 0 0 VANESSA WHITE SVP, CHIEF ADVANCEMENT OFC 379032 0 0 0 1301 0 11550 0 24015 0 415898 0 0 0 FLORENCE GODFREY SVP, CHIEF EXPERIENCE OFC 336016 0 0 0 4993 0 16019 0 28670 0 385698 0 0 0 PART I, LINE 7 LLS AWARDS NON-FIXED PAYMENTS SUCH AS BONUSES ON A DISCRETIONARY BASIS TIED TO THE EMPLOYEE PERFORMANCE AND ORGANIZATION TARGETS. THE NAMES OF EMPLOYEES AND THE AMOUNTS THAT WERE PAID ARE FOUND ON SCHEDULE J, PAGE 2,PART II, COL (B) (II). X 193 3141651 FAIR MARKET VALUE X 9 67424 FAIR MARKET VALUE X VARIOUS OTHER 9 59309 FAIR MARKET VALUE X PRINTED ITEMS 1 2500 FAIR MARKET VALUE 0 0 1 0 SCHEDULE M - SUPPLEMENTAL INFORMATION PART I, COLUMN B LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. FORM 990, PART VI, SECTION A, LINE 4 DURING THE TAX YEAR, LLS AMENDED ITS BYLAWS EFFECTIVE FEBRUARY 3, 2024. THE BYLAW AMENDMENTS INCLUDED THE CREATION OF AN OPERATIONS COMMITTEE OF THE BOARD OF DIRECTORS TO OVERSEE LLS' OPERATIONAL PLANS, DESIGNATED OFFICER POSITIONS FOR LLS' GENERAL COUNSEL AND CHIEF PEOPLE OFFICER AND INCLUDED A REQUIREMENT THAT A CHAIRPERSON AND VICE CHAIRPERSON MUST SERVE AS A DIRECTOR FOR 1 TERM PRIOR TO THEIR ELECTION TO THE POSITION. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, SENIOR VICE PRESIDENT OF FINANCE, VICE PRESIDENT, CONTROLLER, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C ALL EMPLOYEES, VOLUNTEERS, CONSULTANTS, TEMPORARY EMPLOYEES, LOCAL BOARD MEMBERS, AND MEMBERS OF THE NATIONAL BOARD OF DIRECTORS ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL CONFLICT OF INTEREST DISCLOSURE FORMS ARE REVIEWED BY THE LEGAL DEPARTMENT AND, IF DEEMED NECESSARY, ESCALATED TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS FOR FURTHER REVIEW, EVALUATION, AND/OR MANAGEMENT OF ANY ACTUAL OR APPARENT CONFLICTS OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE TALENT AND COMPENSATION COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. THEIR DECISION IS INCLUDED IN THE APPROPRIATE MINUTES OF THE MEETING IN WHICH APPROVAL WAS GIVEN. IN JUNE 2023, THE TALENT AND COMPENSATION COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES. IN 2023, THE TALENT AND COMPENSATION COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS. FORM 990, PART VI, SECTION C, LINE 19 THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 14,796,303. MANAGEMENT AND GENERAL EXPENSES 3,927,127. FUNDRAISING EXPENSES 3,169,711. TOTAL EXPENSES 21,893,141. FORM 990, PART XI, LINE 9: FOREIGN CURRENCY ADJUSTMENTS 335,200. BEAT AML LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH NY 4987820 -56200 LLS LLS PEDAL INITIATIVE LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH NY 10885329 3394697 LLS LLS TAP MIRAGEN LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE LLS LLS TAP X4 LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE LLS LLS TAP LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE 931402 10401740 LLS LLS TAP CONSTELLATION LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE LLS LLS TAP KDAC LLC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 RESEARCH DE LLS THE LLS OF CANADA 804 2 LANSING SQUARE TORONTO CA M2J4P8 PART VII CA N/A 0 THE LLS RESEARCH FOUNDATION 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 133709252 PART VII DE 501(C)(3) LINE 12A, I LLS INC 1 THE LLS RESEARCH PROGRAMS INC 1201 15TH STREET NW SUITE 410 WASHINGTON DC 20005 133470494 PART VII DE 501(C)(3) LINE 12A, I LLS INC 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0